X4 Pharmaceuticals, Inc. Common Stock (XFOR) — 分析摘要
X4 Pharmaceuticals, Inc. Common Stock（XFOR）的市值为381.99百万美元，最近一年的营收同比增长了+1273.2%。净利润率为-225.6%。当前市盈率为-3.8倍。
核心要点
- 营收同比变化+1273.2%
- 净利润率-225.6%
- 市盈率-3.8倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，XFOR的营收增长为+1273.2%，市盈率为-3.8倍。
X4 Pharmaceuticals, Inc. Common Stock (XFOR)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -11.1x — 盈利不足以覆盖利息支出
营业利润率为 -1084.4% — 严重经营亏损
净利率为 -1106.3% — 亏损超过收入（可能含一次性费用）
营收较上一期下降 74.3%。
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
45
总部
BOSTON, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。